We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blocking a Cell Cycle Inhibitor Stimulates Replication of Insulin-Producing Beta Cells

By LabMedica International staff writers
Posted on 27 Jan 2014
Diabetes researchers have found that they could stimulate replication of mature pancreatic beta cells by blocking the activity of the cell cycle inhibitor protein p57Kip2.

The CDKN1C gene encodes the protein p57Kip2, which is a potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. More...
It is a negative regulator of cell proliferation and may play a role in the maintenance of the nonproliferative state throughout life. It is expressed in the heart, brain, lung, skeletal muscle, kidney, pancreas, and testis.

Investigators at the University of Pennsylvania (Philadelphia, USA) and their colleagues at the Hebrew University of Jerusalem (Israel) used short hairpin RNA (shRNA) to suppress the CDKN1C gene in human beta cells obtained from deceased adult donors.

They reported in the January 16, 2014, online edition of the Journal of Clinical Investigation that when human pancreatic tissue with inhibited p57Kip2 activity was transplanted into hyperglycemic, immunodeficient mice, beta cell replication increased more than three-fold. The newly replicated cells retained properties of mature beta cells, including the expression of beta cell markers such as insulin, PDX1, and NKX6.1. Furthermore, these newly replicated cells demonstrated normal glucose-induced calcium influx, further indicating beta cell functionality.

These results showed that beta cells from older humans, in which baseline replication is negligible, could be coaxed to reenter and complete the cell cycle while maintaining mature beta cell properties. Controlled manipulation of this pathway holds promise for the expansion of beta cells in patients with type II diabetes.

Related Links:

University of Pennsylvania
Hebrew University of Jerusalem



Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Research team leader Professor Klaus Gerwert and study lead author Dr. Grischa Gerwert in a betaSENSE laboratory (Photo courtesy of Dennis Yenmez/Stadt Bochum)

Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s

Alzheimer’s disease and Parkinson’s disease are increasing as populations age, yet diagnosis remains largely symptom-driven and often occurs after irreversible brain damage has begun. Earlier detection,... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.